Epidarex invests in early-stage, high growth life science and health technology companies in under-ventured markets within the UK and them.
Business Model:
Revenue: $0
Employees: 0-0
Address: 7910 Woodmont Ave
City: Bethesda
State: MD
Zip: 20814
Country: US
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, international corporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Contact Phone:
+13012985455
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2022 | Kynos Therapeutics | Seed Round | 0 |
6/2016 | Mironid | Series A | 6.2M |
2/2014 | Edinburgh Molecular Imaging | Series A | 6.6M |
11/2015 | Caldan Therapeutics | Series A | 6.8M |
2/2014 | Confluence Life Sciences | Series A | 1M |
7/2021 | Topas Therapeutics | Series B | 0 |
7/2020 | Macomics | Seed Round | 4M |
12/2014 | Sirakoss | Series A | 4.8M |
6/2018 | AdoRx Therapeutics | Series A | 0 |
2/2016 | Apellis Pharmaceuticals | Series D | 47M |
7/2015 | Confluence Life Sciences | Series B | 2.4M |
11/2022 | Nyra Medical | Series A | 20M |
2/2015 | Enterprise Therapeutics | Series A | 2.5M |
6/2018 | NodThera | Series A | 40M |
4/2015 | Clyde Biosciences | Series A | 2.9M |
1/2021 | Theolytics | Series A | 6.8M |
1/2017 | Eternygen | Series A | 8.5M |
3/2016 | Topas Therapeutics | Series A | 0 |
11/2019 | Lunac Therapeutics | Series A | 3.4M |
5/2022 | Transine Therapeutics | Seed Round | 0 |
11/2021 | Dunad Therapeutics | Series A | 0 |
10/2021 | Leucid Bio | Series A | 15.9M |
7/2021 | Macomics | Seed Round | 0 |
5/2021 | Lunac Therapeutics | Venture Round | 0 |
3/2022 | Epsilogen | Series B | 0 |
5/2015 | Funderbeam | Seed Round | 550.6k |
4/2018 | Enterprise Therapeutics | Series B | 41.3M |
11/2022 | Nyra Medical | Series A | 0 |
6/2021 | RapidPulse | Series A | 0 |
8/2022 | RapidPulse | Series A | 0 |
10/2020 | Topas Therapeutics | Series B | 0 |
9/2020 | Libra Therapeutics | Series A | 29M |
5/2015 | Enterprise Therapeutics | Series A | 3.8M |
11/2016 | Enterprise Therapeutics | Venture Round | 5M |
11/2018 | Epsilogen | Series A | 6.4M |
8/2017 | Apellis Pharmaceuticals | Series E | 0 |
6/2020 | NodThera | Series B | 55M |
6/2017 | Epsilogen | Series A | 2.5M |
3/2021 | Dunad Therapeutics | Seed Round | - |
1/2021 | Slate Bio | Seed Round | 0 |
5/2022 | Transine Therapeutics | Seed Round | 0 |
4/2022 | Kynos Therapeutics | Seed Round | 0 |
3/2022 | Epsilogen | Series B | 0 |
11/2021 | Dunad Therapeutics | Series A | 0 |
10/2021 | Leucid Bio | Series A | 0 |
7/2021 | Topas Therapeutics | Series B | 0 |
7/2021 | Macomics | Seed Round | 0 |
6/2021 | RapidPulse | Series A | 0 |
5/2021 | Lunac Therapeutics | Venture Round | 0 |
3/2021 | Dunad Therapeutics | Seed Round | - |
Name | Price |
---|
Name | Size | Announced Date |
---|